Searchable abstracts of presentations at key conferences in endocrinology

ea0081p5 | Adrenal and Cardiovascular Endocrinology | ECE2022

Group education programme for patients with adrenal insufficiency: evaluation based on patients experiences

Davidse Kirsten , Geilvoet Wanda , Brinkman Lotte , van Eck J.P. , Feelders Richard , Van der Lely Aart Jan

Introduction: Adequate hormone replacement therapy in adrenal insufficiency is essential. Patients should have basic knowledge about their condition and what to do in situations which could trigger an adrenal crisis. Education on how and when hydrocortisone replacement therapy should be adjusted as well as instruction and practice an emergency injection are considered important measures to prevent an adrenal crisis. A standardized nurse-led group-based education programme (GEP...

ea0063oc6.1 | Obesity | ECE2019

Impaired glucose homeostasis in leptin-deficient ob/ob mice is corrected by AZP-3404, a 9-amino acid peptide analog derived from insulin-like growth factor-binding protein 2, a key mediator of leptin action

Culler Michael D , Delale Thomas , Milano Stephane , van der Lely Aart Jan , Abribat Thierry , Clemmons David

The key metabolic hormone, leptin, acts in part through the liver to regulate glucose homeostasis, as well as the maturation of both adipocytes and osteoblasts. These actions have been demonstrated to be mediated by insulin-like growth factor binding protein 2 (IGFBP-2), independent of its ability to bind IGF1. The effects of IGFBP-2 on adipocyte and osteoblast maturation can be localized to a short peptide sequence within the unique heparin binding domain (HBD-1) of IGFBP-2. ...

ea0049gp174 | Pituitary | ECE2017

Efficacy and safety of switching to pasireotide LAR alone or in combination with pegvisomant in acromegaly patients controlled with combination treatment of first-generation somatostatin analogues and weekly pegvisomant (PAPE study): a prospective open-label 48 week study, preliminary results 24 weeks

Muhammad Ammar , van der Lely Aart Jan , Janssen Joop , Neggers Sebastian

Background: Efficacy and safety of combination treatment of pasireotide LAR with pegvisomant (PEGV) has not been studied yet. Switching to Pasireotide LAR in patients previously controlled with long-acting somatostatin analogues (LA-SSAs) and PEGV could reduce the required PEGV dose to normalize serum IGF1 levels, while the effect on glucose metabolism is unknown.Methods: We enrolled 60 acromegaly patients >18 years with acromegaly who had normal IGF...

ea0070aep670 | Pituitary and Neuroendocrinology | ECE2020

Eucaloric very low-carbohydrate ketogenic diet as a new supportive treatment modality for acromegaly?

Coopmans Eva , Berk Kirsten AC , El-Sayed Nour , Neggers Sebastian , Van der Lely Aart Jan

Objective: Acromegaly is caused by a growth hormone (GH)-secreting pituitary tumor and its signs are linked to increasedGH-dependent hepatic insulin-like growth factor I (IGF-I) synthesis. A eucaloric very low-carbohydrate ketogenic diet (euVLCK; < 50 g/day) induces ketosis and reduces portal insulin concentrations, which down-regulate hepatic GH receptors and reduce IGF-I synthesis. Somatostatin receptor ligands (SRLs) reduce GH secretion by the pituitary tumor,resul...

ea0032p695 | Neuroendocrinology | ECE2013

Des-acyl ghrelin acts directly and independently and counteracts acyl-ghrelin-induced neuronal activity in the central melanocortin system of rats

Stevanovic Darko , Delhanty Patric , Themmen Axel , Popovic Vera , Holstege Joan , van der Lely Aart-Jan

Ghrelin, the endogenous GH secretagogue, has an important role in metabolic homeostasis. It exists in two major molecular forms: acylated (AG) and des-acylated (DAG). Many studies suggest different roles for these two forms in energy balance regulation. In the present study, we compared the effects of acute intracerebroventricular (ICV) administration of AG, DAG and their combination (AG+DAG) to young adult Wistar rats on food intake and central melanocortin system modulation....

ea0032p855 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Long-term efficacy of long-acting somatostatin analogues in combination with pegvisomant in 112 acromegaly patients, a retrospective single centre study with follow up for up to 8 years

Franck Sanne , van der Lely Aart-Jan , de Rijke Yolanda , Neggers Sebastian

Introduction: Pegvisomant (PEGV) has an efficacy of >90% to control insulin-like growth factor (IGF-1), however in everyday practice a limited efficacy of 63% was reported.Aim: To assess efficacy in the largest single center cohort of acromegalics using PEGV.Methods: A 112 subjects (65 male) were not controlled with high-dose somatostatin analogues (LA-SRIF) for at least 6 months. To control acromegaly, 109 subjects added PEGV ...

ea0032p856 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Long-term safety of long-acting somatostatin analogues in combination with pegvisomant in 133 acromegalic patients, a retrospective single centre study with follow up for up to 8 years

Franck Sanne , van der Lely Aart-Jan , Koole Rita , de Rooij Felix , Neggers Sebastian

Introduction: Pegvisomant (PEGV) has an efficacy of >90% to control insulin-like growth factor-1. Main safety issues are elevated transaminases that seem to be related to Gilbert’s polymorphisms (GiPism) or gender and tumor-size increase (1).Aim: To assess safety in the largest single center cohort of acromegalics using PEGV.Methods: Results are expressed as median (interquartile-range).One-hundred a...

ea0020p556 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety up to 4.5 years of follow-up in 86 patients

Neggers Sebastian , De Herder Wouter , Janssen Joop , Feelders Richard , Van Der Lely Aart-Jan

Background: We previously reported on the efficacy, safety and Quality of Life of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA.Objective: To assess the long term safety in a larger group of acromegalic patients over a larger period of time; 29.2 (1.2–57.4) months (mean (range)).Design: Pegvisomant was added to SSA mono...

ea0014p128 | (1) | ECE2007

Expression of the neuropeptide cortistatin in haematological malignancies

Dalm Virgil , Staal Frank , Hofland Leo , van der Lely Aart-Jan , van Hagen Martin

Introduction: Cortistatin (CST) is a 17 amino-acid neuropeptide involved in sleep regulation. Due to its structural resemblance to somatostatin (SS), CST binds with high affinity to the 5 known SS receptors. CST also binds to the putative MrgX2 receptor. Previously we demonstrated that various types of human immune cells and tissues as well as lymphoid cell lines express CST mRNA. We suggested that CST plays a regulatory role in immune cell function both in physiological and p...

ea0090ep765 | Pituitary and Neuroendocrinology | ECE2023

‘Needless needles’: Can GH injections be prevented by treatment of deep vitamin D deficiency?

Davidse Kirsten , van Eck Judith , van den Akker Erica , van der Lely Aart-Jan , de Graaff Laura

Introduction: Growth hormone (GH) is not only important for growth during childhood. Also, for (young) adults, growth hormone is important for bone mass, muscle strength and metabolism. GH deficiency (GHD) is a condition that can cause a broad range of adult health issues, if left untreated. Therefore on one hand, it is important to confirm and treat GHD after transfer to adult care. On the other hand, the personal and financial burden of unnecessary growth hormone in...